Aldeyra Therapeutics (ALDX) Free Cash Flow (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Free Cash Flow of -$5.1 million for Q1 2026, up 3.57% on a QoQ basis from -$5.3 million in Q4 2025, and up 59.02% year-over-year from -$3.2 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Free Cash Flow (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Free Cash Flow history runs 14 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- Quarterly Free Cash Flow rose 59.02% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.0 million (up 43.14% YoY) and the FY2025 annual result came in at -$33.3 million, up 22.83% from the prior year.
- Free Cash Flow was -$5.1 million for Q1 2026 at Aldeyra Therapeutics, up from -$5.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $500440.0 in Q4 2023 and bottomed at -$20.0 million in Q2 2022.
- A 5-year average of -$9.9 million and a median of -$10.0 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 104.46% — and 2024, when it tumbled 2505.25%.
- Aldeyra Therapeutics' Free Cash Flow stood at -$11.2 million in 2022, then jumped by 104.46% to $500440.0 in 2023, then tumbled by 2505.25% to -$12.0 million in 2024, then jumped by 55.97% to -$5.3 million in 2025, then gained by 3.57% to -$5.1 million in 2026.
- Business Quant data shows ALDX's Free Cash Flow at -$5.1 million in Q1 2026, -$5.3 million in Q4 2025, and -$7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | -5.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.11 Mn |
| Mar 31, 2026 | -5.11 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Jun 30, 2025 | -8.56 Mn |
| Jun 30, 2025 | -8.56 Mn |
| Mar 31, 2025 | -12.47 Mn |
| Mar 31, 2025 | -12.47 Mn |
| Dec 31, 2024 | -12.04 Mn |
| Dec 31, 2024 | -12.04 Mn |
| Sep 30, 2024 | -7.97 Mn |
| Sep 30, 2024 | -7.97 Mn |
| Jun 30, 2024 | -13.22 Mn |
| Jun 30, 2024 | -13.22 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Dec 31, 2023 | 500,440.00 |
| Dec 31, 2023 | 500,440.00 |